Embolic stroke of undetermined source and patent foramen ovale closure: Practice insights from meta-analysis?
Arka ChatterjeeWilliam B HillegassPublished in: Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2019)
Closure of patent foramen ovale (PFO) in embolic stroke of undetermined source (ESUS) reduces recurrent stroke compared with antiplatelet therapy in select patients but increases risk of atrial fibrillation. Device closure is an attractive option for young patients with an anatomically higher risk PFO and imaging proven ESUS. Benefit of PFO closure in ESUS compared with oral anticoagulation remains undefined.
Keyphrases
- atrial fibrillation
- antiplatelet therapy
- percutaneous coronary intervention
- catheter ablation
- left atrial
- oral anticoagulants
- systematic review
- end stage renal disease
- left atrial appendage
- acute coronary syndrome
- direct oral anticoagulants
- heart failure
- newly diagnosed
- chronic kidney disease
- healthcare
- high resolution
- prognostic factors
- peritoneal dialysis
- randomized controlled trial
- quality improvement
- meta analyses
- photodynamic therapy
- fluorescence imaging
- blood brain barrier